US Geriatric Assessment Practices for Older Adults Undergoing Hematopo... https://t.co/ocZ7uumqC9 In a first of its kind team effort with a so grateful for the commitment and mentorship by all! @MediHumdani,Andy Artz, Paul Carpenter @ASTCT improving our survey methodologies🤞🏼

Places on Earth that look too magical to be real🧵 1. Trollstigen, Norway 🇳🇴

New research from @MSKCancerCenter takes a step toward off-the-shelf CAR T cell therapy for #cancer. Author Karlo Perica explains his and Michel Sadelain's recent study in @Nature that demonstrated cells from healthy donors can be stored for future use.

I'm concerned that the recent @statnews piece re: decline of #BMT by @angRchen could be misleading to the public. Adding some context for consideration in the thread 🧵below:

2024's top 10 advances in biology (🧵) 1. Progress in longevity Blocking the pro-inflammatory cytokine, IL11, extended healthspan and lifespan (in mice!) Old mice without IL11 look healthier, they're stronger, and they live longer https://t.co/Y0Raog12xk

Presentation alert: @DrRichardJLin will share his research on advanced myeloid malignancies at @ASH_hematology later today. #ASH24

Thanks to @JGeriOnc for highlighting our paper as paper of the month! @SamuelJYates @fa_ulle @Ashley_Rosko1 @DrRaulCordoba @AMoKhanMD @DrRichardJLin

Fascinating new study shows that patients with chronic pain who are cared for by more empathic physicians have better outcomes, not just in pain scores but also function and quality of life. #hapc #pallonc

⁦@Karthik_Nath17⁩ giving a fine presentation on our work comparing older siblings to younger matched URDs when PTCy is used. Younger URDs improved disease free survival compared to older siblings. Manuscript coming!

Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial - https://t.co/UCIWB316au #leusm #AML

We reported the longest follow up of using BsAbs in lymphoma. With a median 3.5 years f/u, the DOCR for patients treated with mosunetuzumab is not reached. No relapses post 26 months. Retreatment worked in 10/12 including 7 CRs. https://t.co/TRnSrwzNVa

#Tandem24 Aging SIG Poster Walk Saturday at Noon - begins at Poster 593 - Tell your friends! @JayaniReena @AndrewArtz @ROlinMD @MunshiPashnaMD @DrRichardJLin @Ashley_Rosko1 @HKlepinMD @tanyawildes @ASTCT

Weekend review 📖 What is the right duration of VENETOCLAX with HMA for AML: 7 days vs 14 days vs 21 days or 28 days? Brief review of literature in this 🧵 #leusm #AML

Guess where I am on vacation? Bonus: name this Basillica

Our multisite RCT of integrated specialist #palliativecare in 360 pts undergoing stem cell transplantation demonstrates the superiority of this care model. Very proud to be part of this practice changing study, led by @Areejmd, w/ @JasAWebb and @StephanieLeeMD #ash23 #hapc

If you see an eligible DLBCL patient in CR, does #CART outperform AutoHCT? Only available data by @CIBMTR @mshadman Reminds you to keep an open mind, one size does not fit all 🙏🙏 @ASH_hematology for recognizing our work in Press Release #ASH23

Cost-Utility Analysis of Geriatric Assessment and Management in Older Adults With #Cancer: Economic Evaluation Within 5C Trial | Journal of Clinical Oncology ⁦@JCO_ASCO⁩ #gerionc #geriheme

#CAHON #NYOF conference: @YJanjigianMD @MSKCancerCenter discuss new agents & regimens for gastric cancer and patient selection using biomarkers. Exciting advancements in #precisiononcology! 👩‍⚕️🔬

At the #CAHON #NYOF conference, @michaelwangmd @MDAndersonNews delved into the landscape of mantle cell lymphoma and shared insights on achieving success in the academic world. A session brimming with knowledge! 📚🩺

@lihaoran @YJanjigianMD @MSKCancerCenter @sahuonc @DrRichardJLin @TiansterZhang @ChongPan_HMS CLDN18.2 is a promising biomarker in gastric cancer. I hope we can incorporate it into routine clinical practice!